Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Short term Debt: 2022-2024

Historic Short term Debt for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $37.5 million.

  • NewAmsterdam Pharma Co N.V's Short term Debt rose 134.70% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 134.70%. This contributed to the annual value of $37.5 million for FY2024, which is 198.35% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Short term Debt of $37.5 million as of FY2024, which was up 198.35% from $12.6 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Short term Debt peaked at $37.5 million during FY2024, and registered a low of $4.1 million during FY2022.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Short term Debt value was $12.6 million (recorded in 2023), while the average stood at $18.1 million.
  • Data for NewAmsterdam Pharma Co N.V's Short term Debt shows a peak YoY surged of 203.21% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Short term Debt stood at $4.1 million in 2022, then surged by 203.21% to $12.6 million in 2023, then spiked by 198.35% to $37.5 million in 2024.